Characterization of Reproductive, Metabolic, and Endocrine Features of Polycystic Ovary Syndrome in Female Hyperandrogenic Mouse Models

被引:249
|
作者
Caldwell, A. S. L. [1 ]
Middleton, L. J. [1 ]
Jimenez, M. [1 ]
Desai, R. [1 ]
McMahon, A. C. [2 ]
Allan, C. M. [1 ]
Handelsman, D. J. [1 ]
Walters, K. A. [1 ]
机构
[1] Univ Sydney, ANZAC Res Inst, Androl Lab, Sydney, NSW 2139, Australia
[2] Univ Sydney, ANZAC Res Inst, Biogerontol Lab, Sydney, NSW 2139, Australia
基金
澳大利亚研究理事会; 英国医学研究理事会;
关键词
FOLLICLE-STIMULATING-HORMONE; PRENATAL TESTOSTERONE; ANDROGEN EXCESS; SYNDROME PCOS; TARGETED DISRUPTION; LUTEINIZING-HORMONE; RHESUS-MONKEYS; CYCLING RATS; MICE; DEHYDROEPIANDROSTERONE;
D O I
10.1210/en.2014-1196
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age, causing a range of reproductive, metabolic and endocrine defects including anovulation, infertility, hyperandrogenism, obesity, hyperinsulinism, and an increased risk of type 2 diabetes and cardiovascular disease. Hyperandrogenism is the most consistent feature of PCOS, but its etiology remains unknown, and ethical and logistic constraints limit definitive experimentation in humans to determine mechanisms involved. In this study, we provide the first comprehensive characterization of reproductive, endocrine, and metabolic PCOS traits in 4 distinct murine models of hyperandrogenism, comprising prenatal dihydrotestosterone (DHT, potent nonaromatizable androgen) treatment during days 16-18 of gestation, or long-term treatment (90 days from 21 days of age) with DHT, dehydroepiandrosterone (DHEA), or letrozole (aromatase inhibitor). Prenatal DHT-treated mature mice exhibited irregular estrous cycles, oligo-ovulation, reduced preantral follicle health, hepatic steatosis, and adipocyte hypertrophy, but lacked overall changes in body-fat composition. Long-term DHT treatment induced polycystic ovaries displaying unhealthy antral follicles (degenerate oocyte and/or > 10% pyknotic granulosa cells), as well as anovulation and acyclicity in mature (16-week-old) females. Long-term DHT also increased body and fat pad weights and induced adipocyte hypertrophy and hypercholesterolemia. Long-term letrozole-treated mice exhibited absent or irregular cycles, oligo-ovulation, polycystic ovaries containing hemorrhagic cysts atypical of PCOS, and displayed no metabolic features of PCOS. Long-term dehydroepiandrosterone treatment produced no PCOS features in mature mice. Our findings reveal that long-term DHT treatment replicated a breadth of ovarian, endocrine, and metabolic features of human PCOS and provides the best mouse model for experimental studies of PCOS pathogenesis.
引用
收藏
页码:3146 / 3159
页数:14
相关论文
共 50 条
  • [1] Metabolic features of the reproductive phenotypes of polycystic ovary syndrome
    Moran, Lisa
    Teede, Helena
    HUMAN REPRODUCTION UPDATE, 2009, 15 (04) : 477 - 488
  • [2] A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
    Xue, Ping
    Wang, Zhiqiang
    Fu, Xiaomin
    Vvang, Junjiang
    Punchhi, Gopika
    Wolfe, Andrew
    Wu, Sheng
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2018, (140):
  • [3] Transcriptomic survey of key reproductive and metabolic tissues in mouse models of polycystic ovary syndrome
    Yu Pei
    Sanjiv Risal
    Hong Jiang
    Haojiang Lu
    Eva Lindgren
    Elisabet Stener-Victorin
    Qiaolin Deng
    Communications Biology, 6
  • [4] Transcriptomic survey of key reproductive and metabolic tissues in mouse models of polycystic ovary syndrome
    Pei, Yu
    Risal, Sanjiv
    Jiang, Hong
    Lu, Haojiang
    Lindgren, Eva
    Stener-Victorin, Elisabet
    Deng, Qiaolin
    COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [5] Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects
    Nardo, LG
    Rai, R
    GYNECOLOGICAL ENDOCRINOLOGY, 2001, 15 (05) : 373 - 380
  • [6] Endocrine and metabolic characteristics in polycystic ovary syndrome
    Glintborg, Dorte
    DANISH MEDICAL JOURNAL, 2016, 63 (04):
  • [7] Polycystic ovary syndrome: an endocrine and metabolic disease
    Scarpitta, AM
    Sinagra, D
    GYNECOLOGICAL ENDOCRINOLOGY, 2000, 14 (05) : 392 - 395
  • [8] Analysis on endocrine and metabolic features of different phenotypes of polycystic ovary syndrome patients
    Li, Feng
    Yao, Li
    Wu, Hong
    Cao, Shihong
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 29 (05) : 1735 - 1738
  • [9] Endocrine-metabolic features in women with polycystic ovary syndrome during pregnancy
    Paradisi, G
    Fulghesu, AM
    Ferrazzani, S
    Moretti, I
    Proto, C
    Soranna, L
    Caruso, A
    Lanzone, A
    HUMAN REPRODUCTION, 1998, 13 (03) : 542 - 546
  • [10] Hyperandrogenic anovulation (the polycystic ovary syndrome) - back to the ovary?
    Ben-Shlomo, I
    Homburg, R
    Shalev, E
    HUMAN REPRODUCTION UPDATE, 1998, 4 (03) : 296 - 300